Hematologist
CION Cancer Clinics
Secondary AML after earlier cancer treatment | CION Cancer Clinics
Secondary AML is a new leukaemia that develops after earlier chemotherapy, radiotherapy or a marrow disorder. It is not the first cancer coming back. It is rare, and most people treated for cancer never develop it. It is often harder to treat than AML that appears on its own, so fitness, genetic tests and transplant planning shape the plan early. This page explains why it happens and what to ask. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is secondary AML after chemotherapy?
- Which earlier treatments and conditions are linked to it?
- How is it different from AML that appears on its own?
- What happens once secondary AML is suspected?
- How is secondary AML treated?
- What do families often believe, and what is true?
- What do the words on the report mean?
- Common questions about secondary AML
The short answer
What is secondary AML after chemotherapy?
Secondary AML is acute myeloid leukaemia that develops because of an earlier treatment or an earlier blood disorder. When it follows chemotherapy or radiotherapy for another cancer, doctors call it therapy-related AML. It is a new cancer, not the old one coming back.
How an old treatment can lead to a new leukaemia
Chemotherapy and radiotherapy work by damaging the DNA of fast-growing cells. Most of the damage lands on the cancer. Some can also reach the stem cells in the bone marrow that make every blood cell. In a small number of people, one damaged stem cell survives, keeps its faults and years later grows into a leukaemia.
How rare it is
Most people who have had chemotherapy never develop it. The treatment you had was given because the benefit against your first cancer was far larger than this risk. Knowing about it is useful, but it is not a reason to regret having been treated.
What this page cannot tell you
It cannot tell you whether your new blood report means secondary AML, or what your own outlook is. A bone marrow test, the genetic changes in the leukaemia cells and your health after the first cancer decide that.
Bring the treatment summary from your first cancer. The names of the medicines and any radiotherapy matter.The known links
Which earlier treatments and conditions are linked to it?
Your haematologist will ask exactly what you received before. These are the main groups they are looking for.
Alkylating agents
A large group of older chemotherapy medicines used for many cancers. The leukaemia tends to appear several years later, and often starts as MDS, a marrow disorder that makes poorly formed blood cells.
Examples you may see
- Cyclophosphamide
- Melphalan
- Chlorambucil
Topoisomerase II inhibitors
Medicines that stop cancer cells untangling their DNA. The leukaemia linked to them tends to appear sooner than with alkylating agents, and usually without an MDS stage first.
Examples you may see
- Etoposide
- Doxorubicin and epirubicin
Radiotherapy
Radiotherapy that covers a large area of active bone marrow, such as the pelvis or spine, adds to the risk, especially when combined with chemotherapy.
An earlier blood disorder
AML can also grow out of MDS or a myeloproliferative neoplasm (a condition where the marrow makes too many blood cells) that was there before. This is secondary AML too, even without any chemotherapy.
Not sure whether this applies to you?
Ask an oncologistSide by side
How is it different from AML that appears on its own?
AML that appears on its own
Secondary or therapy-related AML
No known earlier trigger
Follows chemotherapy, radiotherapy or a marrow disorder
A mix of favourable, intermediate and adverse genetic changes
Adverse changes, such as in chromosomes 5 or 7 or the TP53 gene, are more common
The marrow is usually healthy before the leukaemia
The marrow may already be weakened by earlier treatment
Transplant decided by risk group and response
Transplant is discussed more often, for those fit enough
Plan built around the AML alone
Plan also has to account for the first cancer and past side effects
The next few days
What happens once secondary AML is suspected?
Bone marrow test
A small sample is taken from the back of the hip bone under local numbing. It confirms AML and shows whether it grew out of an earlier marrow disorder.
Genetic tests on the leukaemia
Tests on the chromosomes and genes of the leukaemia cells place it in a risk group. These results matter more for the plan than the fact that it is therapy-related.
A look back at the first cancer
The team checks whether the first cancer is still under control, and how the heart, kidneys and liver have held up after earlier treatment. Some medicines can only be given a limited number of times in a lifetime.
Tumour board and plan
At CION, the case is presented to a tumour board. The plan is then explained to you and your family, including the options that were not chosen and why.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Treatment choices
How is secondary AML treated?
Treatment depends on how fit you are, the genetic changes in the leukaemia and the state of your first cancer. The aim for fitter people is remission (no leukaemia seen in the marrow), often followed by a transplant. For others the aim is control with a gentler treatment.
Intensive chemotherapy
For people who are fit enough, induction chemotherapy is given in hospital. For therapy-related AML, a combined form of daunorubicin and cytarabine packed together in tiny fat bubbles (liposomal) may be chosen. It is not suitable if earlier anthracycline treatment has already weakened the heart.
Stem cell transplant
Because secondary AML often carries adverse genetic changes, a donor stem cell transplant is discussed early for suitable patients. CION's haematology team does not perform transplants; it evaluates the case and coordinates referral with qualified transplant centres. Ask when a donor search should begin.
Gentler treatment
For people who are older, frail, or still recovering from the first cancer, venetoclax with azacitidine is a common choice. It is given mostly as day care. It does not suit everyone, and it is not a route to transplant for all who receive it.
Medicine choices and doses are set only by your treating haematologist.Commonly believed
What do families often believe, and what is true?
"The first doctor made a mistake with the chemotherapy."
Therapy-related AML is a known, rare risk of treatments that save far more lives than they harm. Its appearance does not mean the first treatment was wrong or given badly.
"The old cancer has come back in the blood."
Secondary AML is a different cancer. It comes from blood-forming cells, not from the first tumour, and it needs its own tests and its own treatment plan.
"After two cancers, treatment is pointless."
Many people with secondary AML are treated with real benefit. The outlook is often harder than for AML that appears on its own, but the choices depend on your fitness and the leukaemia's genetics, not only on its history.
"Tiredness and bruising are just after-effects of the old treatment."
Sometimes they are. But new tiredness, easy bruising or repeated infections after cancer treatment deserve a full blood count, not an assumption. Tell your oncologist.
On your report
What do the words on the report mean?
- t-MN or therapy-related myeloid neoplasm
- The umbrella name for AML or MDS that developed after chemotherapy or radiotherapy.
- MDS (myelodysplastic syndrome)
- A marrow disorder that makes poorly formed blood cells. It can come before secondary AML.
- Complex karyotype
- Several chromosome changes found together in the leukaemia cells. It places the AML in a higher-risk group.
- TP53
- A gene that normally helps repair damaged cells. Changes in it are more common in therapy-related AML and affect treatment choices.
- Germline testing
- A test for inherited gene changes. It may be offered if the history suggests a family tendency to cancer.
Questions we are asked
Common questions about secondary AML
How long after chemotherapy can secondary AML appear?
It varies. After alkylating agents it usually appears several years later, often after an MDS stage. After topoisomerase II inhibitors it tends to appear sooner. The risk falls with time, but no fixed point makes it impossible, so keep up your follow-up blood tests.
Could I have prevented it?
No. Nothing you did or did not do caused it, and there is no diet, supplement or lifestyle change known to stop it. Not smoking and keeping follow-up visits are sensible for your health in general, and help catch any change in your counts early.
Is secondary AML harder to treat?
Often, yes. It more often carries adverse genetic changes, and earlier treatment may have weakened the marrow and organs. But each case is different. Some people with therapy-related AML have favourable genetics. Your haematologist will explain where you stand once the marrow results are back.
Will I need a bone marrow transplant?
A transplant is discussed more often in secondary AML, because it gives the strongest chance of lasting control for many fit patients. Whether it suits you depends on your age, fitness, response to treatment and donor availability. Ask early whether your brothers and sisters should be tested as donors.
Does it run in families?
Usually not. It is caused by damage to marrow cells during treatment, not by an inherited gene. A few people carry an inherited change that raises the risk of more than one cancer. If your family has several cancers, your team may suggest genetic counselling.
Can I still get treatment for my first cancer?
Usually the AML is treated first, because it moves faster. If the first cancer also needs attention, the haematology and oncology teams plan the order together at the tumour board. Some hormone tablets can often continue, but only your teams can decide that.
What signs should make me get a blood test?
New tiredness that does not lift, breathlessness, pale skin, easy bruising, small red spots on the skin, bleeding gums or infections that keep returning. Any fever with these needs the emergency department the same day. Otherwise, ask your oncologist for a full blood count soon.
Is treatment covered by Aarogyasri or insurance?
AML treatment is covered under schemes including Aarogyasri, PM-JAY, CGHS, ECHS and EHS, and by many cashless insurance policies. Some policies treat a second cancer differently. Scheme rules change, so check the current rules and your policy with the helpline before admission.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Risk Factors for Acute Myeloid Leukemia (AML)
- Cancer Research UK — Acute myeloid leukaemia (AML)
- Leukemia & Lymphoma Society — Acute Myeloid Leukemia
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Acute Myeloid Leukaemia (AML)The full AML guide, from diagnosis to follow-upAML Risk Groups and What They PredictWhy genetic changes shape the planWhen AML Needs a TransplantWho is considered and when a donor search startsVenetoclax and Azacitidine for Unfit AML PatientsThe gentler option for less fit patients
Talk to us
Diagnosed with AML after earlier cancer treatment?
Share your blood reports and your first cancer's treatment summary. CION's haematology team will review the case and explain the next step. One helpline serves every CION centre.